InterMune Pharmaceuticals Actimmune
Executive Summary
BLA for treatment of osteopetrosis submitted for priority review Aug. 6. Licensed from Genentech, Actimmune (interferon gamma 1-b) is currently marketed for treatment of chronic granulomatous disease